<DOC>
	<DOCNO>NCT02541773</DOCNO>
	<brief_summary>The purpose study understand behaviour certain blood marker patient heart failure undergo cardiac device implantation procedure call cardiac resynchronization therapy ( CRT ) . CRT effective treatment heart failure , 30 % people respond poor outcome ( 1,2 ) . Despite extensive investigation , identify patient continue challenge . The study intend describe change blood marker CRT examine potential clinical value . The idea behind study blood marker alter heart failure change CRT implantation . Furthermore pattern marker expression implant may predict response outcome .</brief_summary>
	<brief_title>Novel Vascular Biomarkers Behaviour Clinical Value Heart Failure CRT</brief_title>
	<detailed_description>Study Design A prospective , non-randomised , self-control study unselected heart failure patient undergoing CRT implantation , recruit within two year All participant CRT implantation University Hospital Coventry Warwickshire screen use eligibility criterion ( outline ) . Participants three assessment within six month ( baseline , 6 week 6 month approximately ) . All visit coincide routine clinical visit CRT implantation interrogation . Assessments three time point include clinical data ( include New York Heart Association functional class ) , quality life measurement ( Minnesota Living Heart Failure questionnaire ) , echocardiography data ( left ventricular volumetric assessment , ejection fraction ) , electrocardiograph , functional capacity ( 6 minute-walk test ) body composition assessment ( air displacement ) . Peripheral blood sample take examine novel vascular biomarkers examine renal function , full blood count , diabetic control ( HBA1c - diabetic ) Brain Natruetic Peptide . Coronary sinus sample take novel vascular biomarkers small proportion cohort . Blood Sampling Storage Participants ask starve two hour rest one hour blood sampling . Coronary sinus blood sample occurs time coronary sinus cannulation contrast inject . Blood sample ( serum/plasma ) take citrate EDTA tube . The sample stand room temperature minimum 30 minute undergo centrifugation within hour . Centrifugation ( 3500rpm 10 minute ) occur room temperature . Samples store -80 freezer . Laboratory Analysis Samples undergo final analysis University Warwick Kings College London . Novel vascular biomarkers heart failure exist protein serum analyse use enzyme-linked immunosorbent assay ( ELISA ) techniques previously outline publication ( 3-6 ) . The specific novel vascular biomarkers represent different aspect adverse ventricular remodelling ; myocardial stress [ Growth Differentiation Factor-15 ] extracellular remodelling [ Matrix Metalloproteinases -2 &amp; -9 , Aminoterminal Propeptides Type I Collagen ( PINP ) , Aminoterminal Propeptides Type III Collagen ( PIIINP ) , Carboxy-Terminal Telopeptide Type I Collagen ( CITP ) ] ( 4-7 ) . These marker undergo quantification use ELISA technique previously describe literature ( 8 , 9 ) . Micro Ribonucleic Acids ( miRNA ) profile undertaken coronary sinus peripheral sample compare take CRT implantation . Responders compare non-responders determine variation profile two distinct group . Profiling quantification perform described previous publication ( 10-12 ) . Specific cardiac miRNA pre-selected screen quantify , especially already proven altered expression heart failure ( 13-16 ) . Device Implantation CRT device ( pacemaker defibrillator ) implant two independent operator single centre standard fashion . CRT implant traditionally left deltopectoral groove . Venous access via cephalic &gt; axillary &gt; subclavian vein ( operator cannulate either vein base individual patient ) . Right ventricular lead majority patient implant right ventricular apex . Right atrial lead plan implanted right atrial appendage . Patients permanent Atrial Fibrillation right atrial lead implant . Coronary sinus cannulate angiography perform roadmap anatomy lead deployment site . The lateral position favour basal/ mid-cavity position . At point coronary sinus cannulation blood sample ( plasma/serum take ) . Post procedure patient undergo target echocardiography chest x-ray film . Post procedure day implant patient undergo CRT interrogation optimisation programming . Echocardiography A focused echocardiographic study assess leave ventricle performed recommend international standard ( 17 ) . The left ventricular systolic diastolic function fully assess . Volumetric assessment perform use Simpson 's method ( 17 ) . Diastolic function assess perform volumetric assessment leave atrium , measure pulse wave inflow ventricular fill TDI lateral septal wall [ apical 4 chamber ] . All scan perform departmental machine [ GE system , Vivid 7 ] operator . Scans perform independently previous scan review scan . Full analysis conduct scan perform . Inter- Intra-Observer Variability Echocardiography Study An inter- intra-observer variability study perform ensure standardisation echocardiographic examination . Twenty percent echocardiogram randomly select measurement conclusion review . An independent cardiologist/ cardiac physiologist ( accredited British Society Echocardiography ) blind select echocardiograms validate reporting measurement examination . Body Composition Air-displacement plethysmography ( Bodpod ) easily accessible safe tool measure body composition ( 18 ) . The assessment reproducible comparable measure body composition ( 18 ) . The major advantage Bodpod safe patient CRT implant . The University Warwick University Hospital Coventry Warwickshire ( UHCW ) one facility Human Metabolic Unit perform Bodpod .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Left ventricular ejection fraction ≤35 % echocardiography 3 . NYHA Class III/IV symptom milder symptom : NYHA I ( LVEF &lt; 35 % QRS &gt; 150msec rest ECG ) NYHA II ( LVEF &lt; 35 % either QRS &gt; 150msec QRS 120149msec Left Bundle Branch Block rest ECG ) 4 . Optimal medical therapy heart failure patient tolerates ( ACEi , BetaBlocker , Mineralocorticoid ) &gt; 3 month 5 . QRS duration ≥120149msec LBBB rest ECG QRS duration &gt; 150msec rest ECG 6 . Patient consent participation study 1 . Acute heart failure decompensation &lt; 6/52 implant 2 . Significant cognitive impairment 3 . Acute coronary syndrome &lt; 6/52 implant 4 . Chronic kidney disease stage V ( require dialysis ) 5 . Terminal illness likely survival &lt; 1 year implant Post Procedure Exclusions : 1 . Failure procedure ( e.g . coronary sinus anatomy ) 2 . Complication result poor/ none biventricular pacing ( e.g . phrenic nerve stimulation , lead displacement/ damage )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Vascular Biomarker</keyword>
	<keyword>miRNA</keyword>
	<keyword>Extracellular Matrix</keyword>
	<keyword>Brain Natruetic Peptide</keyword>
	<keyword>Growth Degradation Factor-15</keyword>
	<keyword>Body Composition</keyword>
</DOC>